TCGA-44-7670-01A-11R-2066-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 47
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.420
- E2F_TARGETS+0.410
- MYC_TARGETS_V2+0.330
- MITOTIC_SPINDLE+0.310
- MYC_TARGETS_V1+0.260
- SPERMATOGENESIS+0.260
- PANCREAS_BETA_CELLS+0.230
- MTORC1_SIGNALING+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
- UV_RESPONSE_UP+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- INTERFERON_GAMMA_RESPONSE-0.340
- INFLAMMATORY_RESPONSE-0.280
- INTERFERON_ALPHA_RESPONSE-0.280
- UV_RESPONSE_DN-0.230
- COAGULATION-0.220
- KRAS_SIGNALING_UP-0.200
- IL6_JAK_STAT3_SIGNALING-0.180
- MYOGENESIS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 53fd72a0-30b5-4488-afb2-e77c2fd6a0d4 | — | — | 0.875 |
| 2 | MDT-AP-0540 | Med | Medulloblastoma | 0.842 |
| 3 | TCGA-MF-A522-01A-11R-A262-07 | — | cohortSQ2 | 0.827 |
| 4 | MDT-AP-2956 | Med | Medulloblastoma | 0.820 |
| 5 | TCGA-HQ-A2OE-01A-11R-A206-07 | — | — | 0.819 |
| 6 | TCGA-56-7823-01B-11R-2247-07 | — | cohortSQ2 | 0.815 |
| 7 | MDT-AP-3401 | Med | Medulloblastoma | 0.814 |
| 8 | TCGA-60-2722-01A-01R-0851-07 | — | cohortSQ2 | 0.814 |
| 9 | TCGA-33-4538-01A-01R-1201-07 | — | cohortSQ2 | 0.813 |
| 10 | TCGA-70-6723-01A-11R-1820-07 | — | cohortSQ2 | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |